| Gene symbol | VEGFC | Synonyms | Flt4-L, LMPH1D, LMPHM4, VRP | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4q34.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor C | ||||
| GTO ID | GTC3498 |
| Trial ID | NCT05930561 |
| Disease | Diabetic Macular Edema |
| Altered gene | VEGFC |
| Therapeutic/Target gene | Target gene|Therapeutic gene |
| Therapy | miRNA|mRNA |
| Treatment | 4D-150 |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 2 Randomized, Active-Controlled, Double-masked Trial of Intravitreal 4D-150 Gene Therapy in Adults With Diabetic Macular Edema (SPECTRA) |
| Year | 2023 |
| Country | United States|Puerto Rico |
| Company sponsor | 4D Molecular Therapeutics |
| Other ID(s) | 4D-150-C002 |
| Vector information | |||||||
|
|||||||
| Cohort1: 4D-150 | |||||||||
|
|||||||||
| Cohort2: Aflibercept | |||||||||
|
|||||||||